Navigation Links
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Date:8/19/2007

LYON, France, Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm-HIFU device with chemotherapy using docetaxel.

The study is a primary treatment therapy program for men suffering from clinically localized but aggressive high risk prostate cancer typically classified as stage T2c. The study began in late 2006 and will enroll a total of 30 men, of which more than 10 have already been treated.

"Combination therapy is well documented as a treatment protocol for men suffering more aggressive prostate cancers," said Dr. Albert Gelet, Edouard Herriot Hospital, Lyon. "Ablatherm-HIFU is a proven effective treatment for localized prostate cancer already with strong clinical support. This study aims to evaluate its use under an additional dedicated protocol for men in the T2c cancer stage where the tumors are known to be more aggressive, creating a higher risk of relapse if the patient is treated with only a localized therapy. It was demonstrated in pre-clinical studies that HIFU improves chemotherapy drug efficacy in the area around burned tissues."

Under the approved protocol by French Ethical Committee, patients are administered a dose of docetaxel 30 minutes prior to a standard primary indication HIFU session lasting an average of two hours. The Ablatherm-HIFU ablates the prostate tissue according to conventional procedures and protocols. All treatments are administered at Edouard Herriot Hospital in Lyon, France.

"EDAP has a strong scientific and clinical base underlying the Ablatherm-HIFU, with constant work to enhance and extend the capabilities of the device," said Pr John Rewcastle, Medical Director for EDAP. "With already well documented specialized protocols for primary therapy, HIFU retreatment and salvage th
'/>"/>

SOURCE EDAP TMS S.A.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... Nov. 19 In a series of ...ce, Heska Corporation (Nasdaq: HSKA ) ("Heska" or...new and improved website. The upgraded site is th... programming to align the site with the company,s ...Logo: http://www.newscom.com/cgi-bin/prnh/200006...
(Date:11/19/2009)..., Nov. 19 Ligon Discovery, Inc., w...chnology to find drugs against high-value targets,...nancing led by incTANK Ventures. The company will ...campaign that will screen over 100 high-value dise... Ventures General Partner Christian Bailey joins t...
(Date:11/19/2009)... Nov. 19 Impliant, Inc., a develop...onal spinal fusion surgery, announced today that i... team as the Vice President of Clinical and Regula....com/cgi-bin/prnh/20080527/NETU060LOGO ) ,, M...y experience in the spinal and medical device fiel...
Breaking Medicine Technology:Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 1Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 2Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 3Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 4Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 1Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 3Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap Eye in Neovascular Age Related Macular Degeneration 28Wet AMD 29 4988 1Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap Eye in Neovascular Age Related Macular Degeneration 28Wet AMD 29 4988 2Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap Eye in Neovascular Age Related Macular Degeneration 28Wet AMD 29 4988 3Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap Eye in Neovascular Age Related Macular Degeneration 28Wet AMD 29 4988 4Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap Eye in Neovascular Age Related Macular Degeneration 28Wet AMD 29 4988 5
(Date:11/20/2009)...ood pressure readings in children with chronic kid...n during doctor,s office visits increasing a chil...research from Johns Hopkins Children,s Center and ...rs online in the Journal of American Society of Ne...e measurements obtained during regular doctor visi...
(Date:11/20/2009)... save up to one-third buying 90-day supply, study ...s) -- Buying a three-month supply of prescription ...-month supply, according to a new study. , U.S....for 395 drugs between 2000 and 2005, and found tha... of a one-month supply saved an average 29 percent...
(Date:11/20/2009)..., Project Bread addresses increased food insec..., Nov. 20 Project Bread...leased numbers from its upcoming annual status rep... trends described in this report, caused by high u...wealth struggling with hunger. Food insecurity has...
(Date:11/20/2009)..., BATON ROUGE, La., Nov. 20 /PRNewswire-USNewswi... (LAHP) today warned that Louisianians could exper...fits if proposals being considered by Congress sho...f executive officer for LAHP, "Louisiana health pl...m since the beginning of the national debate. Our...
(Date:11/20/2009)... MARINA DEL REY, Calif., Nov. 20 H... President Dr. Richard Merkin, announce that as of... as well as all its affiliated entities, have been...f the HPN family. ,, "We first and foremost wan...the HPN family are dedicated to maintaining the hi...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 2Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 3
..., May 22 Parks Associates and CEA(R) today,announ... pre-show session,at CONNECTIONS(TM) on June 24. T...industry coalition of the finest healthcare and te...health solutions that fosters independence, empowe...
...nal Effects Significant for Adult Acne Sufferers, ... be,viewed as a teenage "rite of passage," results...day show that acne is a problem that also,commonly...d a basic lack of knowledge may be preventing or h...
... Announces Fundraiser As Part Of Its Summer-Long H...lebration Promotion, MILWAUKEE, May 22 Miller Br... Dystrophy Association (MDA) for every Miller Lite... the official beer sponsor of this summer,s Harley...
...USTON - Efforts to protect the tumor-suppressor p5... the protein, causing cancer cells to thrive and s...ientists at The University of Texas M. D. Anderson...d to make sure we first know what version of this ...
... Pharmaceutical Company Honors Former CEO with Per...a Mater, PHILADELPHIA, May 22 GlaxoSmithKline (N... fellowships totaling $500,000,in honor of former ...rs of Business Administration from the school in 1...
...se Distributor to Expand Global Reach of Novel Tec...oscience,leaders in real-time measurement of cellu...Corporation will become the exclusive supplier of ...he recent acquisition of Millennium by Takeda,Phar...
Other Medicine News:Health News:Continua Health Alliance Provides Insight Into Next Generation of Digital Health at CONNECTIONS(TM) 2Health News:Acne - Not Just a Teen Issue 2Health News:Acne - Not Just a Teen Issue 3Health News:Acne - Not Just a Teen Issue 4Health News:Acne - Not Just a Teen Issue 5Health News:Acne - Not Just a Teen Issue 6Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 3Health News:Stabilizing cancer-fighting p53 can also shield a metastasis-promoter 2Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 2Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 3Health News:Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 2
...men tube made of silicone rubber with a wire reinf...teristics of silicone rubber, Silbronco is soft an...hermore, the tube will not soften like PVC tubes, ...ry., ,Silbronco is also especially useful when a ...
Cohen Tip Deflecting Endobronchial Blocker Set
Arndt Endobronchial Blocker - Spherical Balloon
QuickTrach
Medicine Products: